Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients

Pilot Study to Compare the Humphrey Field Analyzer (HFA) 30-2 Swedish Interactive Threshold Algorithm (SITA) Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE), Using a New Fast GATE (German Adaptive Threshold Estimation) in Glaucoma Patients Under Topic Therapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00902109

Acronym

TRASCO

Enrollment

Registered

2009-05-14

Start date

2010-04-30

Completion date

2016-12-31

Last updated

2016-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open Angle Glaucoma (POAG)

Keywords

visual field, perimetry, progression, POAG, glaucoma

Brief summary

The purpose of this study is to compare the two psychophysical perimetric techniques regarding progression of the visual field.

Interventions

DEVICEPerimetry

different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold

DEVICEConfocal Scanning Laser Tomography

HRT examinations for the clinical evaluation of the optic disc.

DEVICEOptical Coherence Tomography (OCT)

imaging of the retinal nerve fiber layer

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* primary open angle glaucoma (POAG) * spherical ametropia max. ± 8 dpt * cylindrical ametropia max. ± 3 dpt * distant visual acuity \> 10/20 * pupil diameter \> 3 mm

Exclusion criteria

* diabetic retinopathy * asthma * history of epilepsy or significant psychiatric disease * medications known to effect visual field sensitivity * infections (e.g., keratitis, conjunctivitis, uveitis) * severe dry eyes * miotic drug * squint * nystagmus * albinism * any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields * keratoconus * intraocular surgery (except for uncomplicated cataract surgery) performed \< 3 month prior to screening * history or signs of any visual pathway affection other than glaucoma * history or presence of macular disease and/or macular edema, ocular trauma, medications known to affect visual field sensitivity

Design outcomes

Primary

Measure	Time frame	Description
Comparison of rate of progression	36 month	Perimetric measures every 3 month over 3 years

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026